vs
Side-by-side financial comparison of CLEANSPARK, INC. (CLSK) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
CLEANSPARK, INC. is the larger business by last-quarter revenue ($181.2M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 11.6%). Over the past eight quarters, CLEANSPARK, INC.'s revenue compounded faster (106.4% CAGR vs 10.6%).
CleanSpark, Inc. is a U.S.-headquartered sustainable technology company operating two core business segments: low-carbon Bitcoin mining powered primarily by renewable and stranded energy resources, and end-to-end microgrid design, deployment, and operation services for commercial, industrial, and public sector clients across North America.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
CLSK vs ESPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $181.2M | $168.4M |
| Net Profit | $-378.7M | — |
| Gross Margin | 47.2% | — |
| Operating Margin | -174.7% | 50.6% |
| Net Margin | -209.0% | — |
| Revenue YoY | 11.6% | 143.7% |
| Net Profit YoY | -253.5% | — |
| EPS (diluted) | — | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $181.2M | $168.4M | ||
| Q3 25 | — | $87.3M | ||
| Q2 25 | — | $82.4M | ||
| Q1 25 | — | $65.0M | ||
| Q4 24 | — | $69.1M | ||
| Q3 24 | $89.3M | $51.6M | ||
| Q2 24 | $104.1M | $73.8M | ||
| Q1 24 | $111.8M | $137.7M |
| Q4 25 | $-378.7M | — | ||
| Q3 25 | — | $-31.3M | ||
| Q2 25 | — | $-12.7M | ||
| Q1 25 | — | $-40.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-62.2M | $-29.5M | ||
| Q2 24 | $-236.2M | $-61.9M | ||
| Q1 24 | $126.7M | $61.0M |
| Q4 25 | 47.2% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 36.0% | — | ||
| Q2 24 | 56.6% | — | ||
| Q1 24 | 69.3% | — |
| Q4 25 | -174.7% | 50.6% | ||
| Q3 25 | — | -11.4% | ||
| Q2 25 | — | 8.6% | ||
| Q1 25 | — | -34.0% | ||
| Q4 24 | — | -6.4% | ||
| Q3 24 | -73.5% | -31.0% | ||
| Q2 24 | -239.2% | 3.5% | ||
| Q1 24 | — | 52.5% |
| Q4 25 | -209.0% | — | ||
| Q3 25 | — | -35.9% | ||
| Q2 25 | — | -15.4% | ||
| Q1 25 | — | -62.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -69.6% | -57.2% | ||
| Q2 24 | -226.9% | -83.9% | ||
| Q1 24 | 113.4% | 44.3% |
| Q4 25 | — | $0.32 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.21 | ||
| Q4 24 | — | $-0.14 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | — | $-0.33 | ||
| Q1 24 | — | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $458.1M | $167.9M |
| Total DebtLower is stronger | $1.8B | — |
| Stockholders' EquityBook value | $1.4B | $-302.0M |
| Total Assets | $3.3B | $465.9M |
| Debt / EquityLower = less leverage | 1.29× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $458.1M | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | — | $144.8M | ||
| Q3 24 | $121.2M | $144.7M | ||
| Q2 24 | $126.1M | $189.3M | ||
| Q1 24 | — | $226.6M |
| Q4 25 | $1.8B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $7.2M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $5.1M | — |
| Q4 25 | $1.4B | $-302.0M | ||
| Q3 25 | — | $-451.4M | ||
| Q2 25 | — | $-433.5M | ||
| Q1 25 | — | $-426.2M | ||
| Q4 24 | — | $-388.7M | ||
| Q3 24 | $1.8B | $-370.2M | ||
| Q2 24 | $1.4B | $-344.2M | ||
| Q1 24 | $1.5B | $-294.3M |
| Q4 25 | $3.3B | $465.9M | ||
| Q3 25 | — | $364.0M | ||
| Q2 25 | — | $347.1M | ||
| Q1 25 | — | $324.0M | ||
| Q4 24 | — | $343.8M | ||
| Q3 24 | $2.0B | $314.1M | ||
| Q2 24 | $1.5B | $352.3M | ||
| Q1 24 | $1.5B | $373.1M |
| Q4 25 | 1.29× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-161.1M | $45.2M |
| Free Cash FlowOCF − Capex | $-198.1M | — |
| FCF MarginFCF / Revenue | -109.3% | — |
| Capex IntensityCapex / Revenue | 20.4% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-626.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-161.1M | $45.2M | ||
| Q3 25 | — | $-4.3M | ||
| Q2 25 | — | $-31.4M | ||
| Q1 25 | — | $-22.6M | ||
| Q4 24 | — | $-35.0M | ||
| Q3 24 | $-233.7M | $-35.3M | ||
| Q2 24 | $-58.4M | $-7.2M | ||
| Q1 24 | $-44.8M | $53.8M |
| Q4 25 | $-198.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-299.8M | $-35.5M | ||
| Q2 24 | $-68.7M | $-7.3M | ||
| Q1 24 | $-60.3M | $53.8M |
| Q4 25 | -109.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -335.8% | -68.7% | ||
| Q2 24 | -66.0% | -9.9% | ||
| Q1 24 | -54.0% | 39.0% |
| Q4 25 | 20.4% | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 74.0% | 0.3% | ||
| Q2 24 | 9.9% | 0.1% | ||
| Q1 24 | 13.8% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.35× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLSK
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
